2C-T-36, also known as 2,5-dimethoxy-4-(trifluoromethylsulfanyl)phenethylamine or 2C-T-TFM as well as CYB210010 or CYB2108, is a psychedelic drug of the phenethylamine and 2C families.
Use and effects The properties and effects of 2C-T-36 in humans appear to be unknown.
Interactions
Pharmacology Pharmacodynamics 2C-T-36 has a Ki of 0.35nM at the serotonin 5-HT2A receptor, and an of 4.1nM at the serotonin 5-HT2A receptor and 7.3nM at the serotonin 5-HT2C receptor, compared to 88nM at the serotonin 5-HT2B receptor. It is a potent, selective, long acting, and orally active agonist for the serotonin 5-HT2A and 5-HT2C receptors and produces psychedelic-like responding in several different animal species. The interactions of 2C-T-36 with numerous other receptors and targets have also been described.
Chemistry Synthesis The chemical synthesis of 2C-T-36 has been described.
Analogues
Analogues of 2C-T-36 (2C-T-TFM) include 2C-T-21 (2C-T-FE), 2C-T-21.5 (2C-T-DFE), 2C-T-22 (2C-T-TFE), 2C-T-28 (2C-T-FP), 2C-T-35 (2C-T-DFM), 2C-T, 2C-TFM, and 2C-TFE, among others. Some other analogues include 2C-Se-TFM, trifluoromescaline (TFM), 3C-TFE (3C-trifluoroescaline), and tiflorex (flutiorex). A deuterated isotopologue, CYB2108D (2C-T-36 with fully deuterated methoxy groups at 2 and 5 positions), is known.
History Alexander Shulgin attempted to synthesise this compound in the 1990s, and mentions it in his book PiHKAL (Phenethylamines I Have Known and Loved) under the entry for 2C-T-21, but was unsuccessful in producing a key intermediate and never assigned it a 2C-T number. "A couple of additional efforts warrant comment. The reaction between trifluoromethyliodide and 2,5-dimethoxythiophenol should have produced 2,5-dimethoxyphenyl trifluoromethyl sulfide, but it didn't produce anything." 2C-T-36 was ultimately first synthesised and named by Geoffrey Varty and colleagues at Irish biopharmaceutical company Helus Pharma (formerly Cybin) in 2023.
Society and culture Legal status Canada 2C-T-36 is a controlled substance in Canada under phenethylamine blanket-ban language.
United States The drug is not an explicitly controlled substance in the United States.
Research Other related drugs under development by Helus Pharma (formerly Cybin) include the deuterated phenethylamine HLP005 (CYB005) and the deuterated tryptamines deupsilocin (HLP003; CYB003) and deudimethyltryptamine (HLP004; CYB004).
See also 2C (psychedelics) List of investigational hallucinogens and entactogens
References
External links 2C-T-TFM - Isomer Design